Guardant Health (GH) Appoints Manuel Hidalgo Medina to its Board

Guardant Health, Inc. (NASDAQ: GH), a pioneer in precision oncology, today announced the appointment of Dr. Manuel Hidalgo Medina to its board of directors, effective immediately. Dr. Hidalgo currently serves as Chief of the Division of Hematology and Medical Oncology at Weill Cornell Medicine and NewYork-Presbyterian/Weill Cornell Medical Center.

“Dr. Hidalgo brings a wealth of expertise and leadership in translational and clinical research, particularly in anticancer drug development,” said Helmy Eltoukhy, chairman and co-CEO of Guardant Health. “His extensive experience in precision oncology and his commitment to advancing oncology care make him an invaluable addition to our board.”

At Weill Cornell Medicine, Dr. Hidalgo oversees clinical and translational research in hematology and medical oncology, where he is the Walter B. Wriston Professor of Pancreatic Cancer Research.

“With Guardant Health's innovative approaches to cancer detection and care, I am eager to contribute to their mission of improving patient outcomes through advanced diagnostics,” said Dr. Hidalgo. “I look forward to collaborating with the leadership team to accelerate the development and adoption of precision oncology solutions.”

Dr. Hidalgo’s distinguished career includes prior roles as chief of the Division of Hematology at Beth Israel Deaconess Medical Center in Boston, clinical director of the Rosenberg Clinical Cancer Center, and leadership positions at the Spanish National Cancer Research Centre (CNIO) in Madrid and the Kimmel Comprehensive Cancer Center. Dr. Hidalgo is also a member of the board at Bristol Myers Squibb.

You May Also Be Interested In

• Stripe, Advent In Talks To Buy Paypal - WSJ
• Mosaic sets pricing for tender offers on up to $1.4B in debt
• Hydrofarm Holdings Group, Inc. (HYFM) Misses Q2 EPS by 134c